A prevention gap in a high-risk group
People with Lynch syndrome face a substantially elevated inherited risk of colorectal cancer and several other cancers. Regular surveillance is a central part of care, but research has also pointed to a potential preventive role for acetylsalicylic acid, better known as aspirin.
A survey led by researchers at University Hospital Bonn highlights a gap between awareness of prevention and use of aspirin in this group. Of 539 people with Lynch syndrome surveyed across Germany between December 2025 and February 2026, about 97% knew the specific screening recommendations and nearly all reported regular colonoscopies. Yet only 10.4% said they were currently taking aspirin.
The finding does not establish why every respondent did or did not use aspirin. But it shows that strong participation in screening does not automatically translate into uptake of a medication-based prevention strategy, even when people are open to considering new approaches.
Why dose matters
Earlier evidence from the CAPP2 study showed that aspirin could significantly reduce the long-term risk of colorectal cancer in people with Lynch syndrome. That study examined a comparatively high daily dose of 600 milligrams.
The recently published international CaPP3 study now suggests that a much lower daily dose, 100 milligrams, could have a similar cancer-preventive effect while producing fewer side effects, particularly bleeding complications. If supported by further evidence and incorporated into clinical practice, a lower-dose approach could make the preventive option easier to discuss and potentially more tolerable for many patients.
The Bonn researchers stress that this is not a simple declaration of equivalence between the two doses. The statistical criteria for formal equivalence were not met in every analysis, according to corresponding author Dr. Robert Hüneburg. That means the lower-dose findings should still be interpreted carefully rather than treated as a settled replacement for the earlier regimen.
A changing evidence base
The German survey was designed and conducted before the CaPP3 results were published. It therefore captures aspirin use under the evidence available at that time, rather than measuring how people and clinicians will respond to the newer lower-dose findings.
That timing makes the survey useful as a baseline. It suggests that future work will need to determine whether evidence for a lower daily dose changes real-world adoption. Researchers will also need to understand how patients weigh possible benefits against the known concern of bleeding complications, and how advice is communicated alongside existing surveillance programs.
For now, the central message is not that everyone with Lynch syndrome should begin aspirin independently. Aspirin use for prevention involves individual medical considerations, including potential harms. The research instead adds to the discussion between patients and their clinical teams about whether a lower-dose option may be appropriate.
Screening and prevention are not interchangeable
The survey’s high reported awareness of screening recommendations and regular colonoscopy use is important context. Surveillance looks for disease or changes that may develop; preventive medication aims to reduce risk before cancer occurs. The two approaches can complement one another, but one does not simply replace the other.
The new evidence may give clinicians and patients a more practical conversation to have: whether the potential long-term benefit associated with aspirin can be pursued at a dose that may be better tolerated. The answer will depend on additional research, clinical guidance and a person’s own circumstances.
For a hereditary cancer-risk population already engaged with screening, the challenge is now translating evolving evidence into clear, balanced preventive choices. The CaPP3 findings offer a promising possibility, but the researchers’ caution is equally important: lower-dose aspirin may be a practical option for many people with Lynch syndrome, not yet a universal conclusion.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
